biostudies-literatureUnknown15Hontecillas-Prieto L<h4>Background</h4>Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.<h4>Methods</hFrontiers in immunology1293931https://www.ebi.ac.uk/biostudies/studies/S-EPMC10926187biostudies-literatureCD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.PMC10926187de la Cruz-Vicente FGuirado-Risueno MHontecillas-Prieto LJimenez-Cortegana CGalvez-Carvajal LFlores-Campos RRueda-Dominguez ASanchez-Beato MSanchez-Leon MLSilva-Romeiro SGomez-Codina JRios-Herranz EGarcia-Dominguez DJPalazon-Carrion NSanchez-Margalet VMartin Garcia-Sancho ASalar-Silvestre ALabrador JRodriguez-Garcia GNogales-Fernandez ERodriguez-Abreu DFernandez-Alvarez RAlvaro-Naranjo Tde la Cruz-Merino LProvencio-Pulla MGuma-Padro JCarnicero-Gonzalez FMartinez-Banaclocha NCasanova-Espinosa MMarylene LfalseCD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.<h4>Background</h4>Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.<h4>Methods</h2024-01-01T00:00:00Z20242026-04-29T14:33:33.033Z2024-11-20T19:06:27.453ZS-EPMC109261873846929910.3389/fimmu.2024.1293931